Solutions for you to drive healthcare forward

This week's Fierce Biotech is brought to you by IQVIA Biotech.

Trouble viewing? Click here.


 
Strategies for Long-Term Follow-Up of Gene Therapies
Leveraging decentralized approaches and real world data
 
Cell and gene therapies have the potential to transform the lives of patients with life-threatening illnesses. While there is great promise, bringing these new therapies to market is far from simple. One of the biggest challenges is the required long-term follow-up monitoring for up to 15 years.
 
Download the insight brief Long-term follow-up for gene therapies to learn about tailored, patient-centric approaches and more:
  • How to determine when long-term follow-up (LTFU) is needed in clinical trial and approved product settings
  • Clinical considerations in designing LTFU studies for gene therapies
  • Data collection methods to reduce site and patient burden
  • Flexible decentralized approaches to LTFU studies that can reduce risk and improve the patient experience
Your milestones. Your needs. Your team.
 
© 2021 IQVIA Biotech. All rights reserved. IQVIA is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Contact us at iqviabiotech.com
4820 Emperor Boulevard, Durham, NC 27703, USA
83 Wooster Heights Road, Danbury, CT 06810, USA

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.

 


You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017